Processing

Please wait...

Settings

Settings

Goto Application

1. MXMX/a/2008/010893 - IMMUNOMODULATORY AND ANTI-TUMOUR PEPTIDES

Office
Mexico
Application Number MX/a/2008/010893
Application Date 22.08.2008
Publication Number MX/a/2008/010893
Publication Date 31.10.2008
Publication Kind A
IPC
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
C07K 14/435
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
Applicants CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA.*
Inventors REYES ACOSTA, Osvaldo
GUILLÉN NIETO, Gerardo Enrique
UBIETA GÓMEZ, Raimundo
ACEVEDO CASTRO, Boris Ernesto
GARAY PÉREZ, Hilda Elisa
GUERRA VALLESPÍ, Maribel
TORRÉNS MADRAZO, Isis del Carmen
Agents HERIBERTO RAUL LOPEZ PADILLA.*
Priority Data 20060047 24.02.2006 CU
Title
(EN) IMMUNOMODULATORY AND ANTI-TUMOUR PEPTIDES
(ES) PEPTIDOS CON CAPACIDAD ANTI-TUMORAL E INMUNOMODULADORA
Abstract
(EN)
The invention relates to the development of peptides originating from sequence HYRIKPTFRRLKWKKYKGKFW, into which amino acid substitutions have been introduced, which guarantee the dissociation of the lipopolysaccharide-binding capacity and potentiate the anti-tumour and immunomodulatory effect. Said peptides and combinations thereof can be used in the treatment of cancer, as well as in synergism with other standard therapies.

(ES)
La presente invención se relaciona con el desarrollo de péptidos provenientes de la secuencia HYRIKPTFRRLKWKKYKGKFW en la cual se han introducido sustituciones de aminoácidos que garantizan la disociación de la capacidad de unión al lipopolisacárido y potencian el efecto antitumoral e inmunomodulador;estos péptidos o combinaciones de ellos sonútiles para el tratamiento del cáncer, asícomo en sinergismo con las terapias convencionales.